Pharmafile
Is the Current EU Legal Framework for Orphan Medicines Fit for Purpose?
Autumn 2019
Maria Isabel Manley, partner and head of the UK Global Life Sciences Practice, and Chris Boyle, associate, at Sidley, discuss the impact of regulatory frameworks on medicines for rare diseases.
Contacts
Capabilities
Suggested News & Insights
GMP 2026: Regulatory Reliance, AI, and the Future of Pharmaceutical ManufacturingWednesday, December 2, 20262026 Momentum Food and Beverage ExchangeOctober 6-7, 2026Sidley Represents GE HealthCare in Its US$945 Million Acquisition of SOFIE BiosciencesOctober 7, 2026Sidley Represents Telix Pharmaceuticals in Its US$1.65 Billion Merger With ITMOctober 5, 2026GLOBE MFN (Most-Favored-Nation) Drug Pricing for Medicare Part B Significantly Narrowed in Final RuleOctober 5, 2026Sidley Represents Pyxis Oncology in an up to US$282.6 Million Public OfferingOctober 1, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory